Table 2.
Analytical performance of each kit in discriminating SARS-CoV-2 infection.
| Kit, manufacturer, target protein, and Ab measured | Performance | Kappa | |
|---|---|---|---|
| Sensitivity (95% CI) | Specificity (95% CI) | ||
|
cPass sVNT, GenScript, RBD, total |
96.42% (93.51%–98.27%) |
95.24% (89.92%–98.23%) |
0.91 |
|
Elecsys Anti-SARS-CoV-2, Roche, NP, IgG/IgA |
98.92% (96.89%–99.78%) |
100.00% (97.11%–100.00%) |
0.98 |
|
Elecsys Anti-SARS-CoV-2 S, Roche, RBD, total |
98.21% (95.87%–99.42%) |
100.00% (97.11%–100.00%) |
0.97 |
|
SARS-CoV-2 IgG II Quant, Abbott, RBD, IgG |
98.92% (96.89%–99.78%) |
99.21% (95.66%–99.98%) |
0.98 |
For calculating the analytical performance in discriminating SARS-CoV-2 infection, 279 sero-converted sera of confirmed-COVID-19 patients and 126 negative control sera of HCWs were used. The pre-defined cut-off values suggested by the manufacturers were applied.
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; Ab, antibody; sVNT, surrogate virus neutralization test; RBD, receptor-binding domain; NP, nucleocapsid; CI, confidence interval.